AVEO Pharmaceuticals Inc. (AVEO)

1.95
0.01 0.77
NASDAQ : Health Technology
Prev Close 1.96
Open 1.92
Day Low/High 1.89 / 1.97
52 Wk Low/High 1.40 / 3.59
Volume 603.63K
Avg Volume 2.34M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 248.19M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a strong on high relative volume candidate

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment...

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015.

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S.

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data In Cancer Associated Cachexia At 2015 Annual Meeting Of The American Association Of Cancer Research

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data In Cancer Associated Cachexia At 2015 Annual Meeting Of The American Association Of Cancer Research

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a...

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

These under-$10 stocks are within range of triggering breakout trades.

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a strong on high relative volume candidate

AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade

AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade

AVEO Pharmaceuticals (AVEO) stock is up after RBC Capital raised its rating to 'sector perform' from 'underperform.'

AVEO Oncology Reports Full Year 2014 Financial Results

AVEO Oncology Reports Full Year 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014.

AVEO Oncology Announces Presentation Of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared To Bevacizumab In Low Serum NRP-1 Patients With Advanced CRC

AVEO Oncology Announces Presentation Of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared To Bevacizumab In Low Serum NRP-1 Patients With Advanced CRC

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- ( Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase...

Regulators Want Drug Companies to Be Honest About FDA

Regulators Want Drug Companies to Be Honest About FDA

The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.

AVEO Oncology To Host Conference Call To Discuss Presentation Of Final Results And Biomarker Analysis From Phase 2 Study Of Tivozanib In Patients With Advanced Colorectal Cancer

AVEO Oncology To Host Conference Call To Discuss Presentation Of Final Results And Biomarker Analysis From Phase 2 Study Of Tivozanib In Patients With Advanced Colorectal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.

AVEO To Present At The 33rd Annual J.P. Morgan Healthcare Conference

AVEO To Present At The 33rd Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33 rd Annual J.

Michael M. Needle, M.D., Chief Medical Officer (Photo: Business Wire)

Michael M. Needle, M.D., Chief Medical Officer (Photo: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N.

AVEO Receives Confirmation Of Eligibility For Submission Of A Tivozanib Marketing Authorization Application To The European Medicines Agency

AVEO Receives Confirmation Of Eligibility For Submission Of A Tivozanib Marketing Authorization Application To The European Medicines Agency

AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing...

Michael P. Bailey, President And Chief Executive Officer (Photo: Business Wire)

Michael P. Bailey, President And Chief Executive Officer (Photo: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P.

Slim Pickings in Latest 13F Filings

Many value investors are making more concentrated bets.

Shotgun Investing in Biotech

Shotgun Investing in Biotech

Two speculative plays are worthy of consideration.

AVEO Enters Into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF Inhibitor) For The Treatment Of Ocular Diseases

AVEO Enters Into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF Inhibitor) For The Treatment Of Ocular Diseases

AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the...

AVEO Oncology Reports Third Quarter 2014 Financial Results

AVEO Oncology Reports Third Quarter 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.

Leon Cooperman to Cash in on Atlas Energy Acquisition

Leon Cooperman to Cash in on Atlas Energy Acquisition

Doral Financial Corp. (NYSE:DRL), Nanosphere, Inc. (NASDAQ:NSPH) and Atlas Energy LP (NYSE:ATLS) made major gains early in the day this Monday. In the red are DryShips Inc. (NASDAQ:DRYS), Mitek Syst...

AVEO Oncology Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress

AVEO Oncology Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of...

AVEO And Biodesix Announce Exploratory Analysis Of VeriStrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress

AVEO And Biodesix Announce Exploratory Analysis Of VeriStrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify ...

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data At 2nd Cancer Cachexia Conference

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data At 2nd Cancer Cachexia Conference

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), ...

AVEO Oncology Announces Lease Termination And Amendment To Debt Financing Facility

AVEO Oncology Announces Lease Termination And Amendment To Debt Financing Facility

AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters...

Clinical Data On AVEO Oncology’s Ficlatuzumab And Tivozanib To Be Presented At The ESMO 2014 Congress

Clinical Data On AVEO Oncology’s Ficlatuzumab And Tivozanib To Be Presented At The ESMO 2014 Congress

AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular ...

First Week of AVEO April 2015 Options Trading

First Week of AVEO April 2015 Options Trading

Investors in AVEO Pharmaceuticals, Inc. saw new options begin trading this week, for the April 2015 expiration.

AVEO Oncology Reports Second Quarter 2014 Financial Results And Updates Progress On Strategic Plan

AVEO Oncology Reports Second Quarter 2014 Financial Results And Updates Progress On Strategic Plan

AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.

Another Gem for the Biotech Basket

Amid the basket's impressive performance, I'm adding Minerva.

Building a Biotech Basket

Borrowing a page from a master investor's playbook.

TheStreet Quant Rating: D- (Sell)